Welcome to our dedicated page for Revance Therapeutics news (Ticker: RVNC), a resource for investors and traders seeking the latest updates and insights on Revance Therapeutics stock.
Revance Therapeutics, Inc. (symbol: RVNC) is a specialty biopharmaceutical company dedicated to the development, manufacturing, and commercialization of innovative botulinum toxin products for various aesthetic and therapeutic uses. Leveraging its proprietary portfolio of botulinum toxin compounds and the patented TransMTS® peptide delivery system, Revance aims to address unmet needs in the $3 billion neurotoxin market.
The company’s unique TransMTS technology allows for the delivery of botulinum toxin A in two distinctive formulations: a needle-free topical form and an injectable form that targets the site of injection for a potentially longer-lasting effect. Revance is actively pursuing clinical development for two main product candidates: Topical RT001 and Injectable RT002. RT001 is a topical gel with the potential to become the first commercially available non-injectable botulinum toxin dose form.
Additionally, Revance has launched a prestige aesthetics portfolio, which includes the RHA Collection of dermal fillers and the HintMD platform. Their primary products, DaxibotulinumtoxinA for Injection and DaxibotulinumtoxinA for Injection Aesthetics, are central to their aesthetic and therapeutic offerings.
Revance operates through two main business segments: Product and Service. The Products segment, which generates the majority of the company’s revenue, focuses on the research and development of aesthetic and therapeutic products. Recent achievements and ongoing developments reflect the company’s commitment to advancing the field of neuromodulation.
Revance Therapeutics (NASDAQ: RVNC) announces that its Biologics License Application (BLA) for DaxibotulinumtoxinA for Injection remains under FDA review. The company anticipates FDA approval for treating glabellar lines in 2021. While the issuance of a Form 483 is common post-inspection, Revance confidently submitted a response in July 2021. The innovative neuromodulator product DaxibotulinumtoxinA features a proprietary stabilizing peptide excipient, enhancing its market potential.
Revance Therapeutics (NASDAQ: RVNC) has announced the launch of OPUL™, an innovative Relational Commerce Platform tailored for aesthetic practices in the U.S. This cloud-based system integrates payment solutions, data analytics, and enhanced customer service to boost consumer loyalty. Key features include comprehensive practice analytics, customizable checkout options, and transparent payment processing. Revance aims to replace traditional discount-based models, focusing instead on nurturing long-term relationships with clients, addressing the evolving needs of the aesthetic market.
Revance Therapeutics (RVNC) has announced the presentation of Phase 3 trial data for DaxibotulinumtoxinA for Injection at the International Parkinson and Movement Disorder Society (MDS) Virtual Congress from September 17-22, 2021. The ASPEN-1 trial results show a meaningful reduction in cervical dystonia symptoms, highlighting DaxibotulinumtoxinA's long duration of effect and safety. The company plans to file a Supplemental Biologics License Application to advance treatment options for this debilitating condition.
Revance Therapeutics announced the presentation of new data on the effectiveness and safety of its RHA® Collection of dermal fillers for treating moderate-to-severe nasolabial folds in patients with darker skin color. This post-hoc analysis will be showcased at the 2021 Virtual Skin of Color Update meeting from September 10-12, 2021. The findings reinforce Revance's dedication to safety and efficacy in aesthetic treatments, particularly for underrepresented patient populations, underlining its innovation in the aesthetic portfolio.
Revance Therapeutics (Nasdaq: RVNC) announced its participation in the Wells Fargo Securities Healthcare Conference, a fully virtual event on September 9-10. CEO Mark Foley will present on September 9 at 11:40 a.m. CT / 12:40 p.m. ET. Interested parties can access the live audio webcast from the Investor Relations section of their website, with a replay available for 30 days post-event.
Revance focuses on innovative aesthetic and therapeutic products, including the neuromodulator DaxibotulinumtoxinA, which is awaiting U.S. regulatory approval.
Revance Therapeutics announced positive results from a post-hoc analysis of the SAKURA Phase 3 clinical program for DaxibotulinumtoxinA for Injection, focusing on static glabellar lines. The study revealed significant and sustained improvement in static lines with repeated treatments among 568 subjects. Key findings include a 70% reduction in static lines 4 weeks after the third treatment cycle and a 54.4% complete elimination rate after the first treatment. Results were published in Dermatologic Surgery, indicating potential for dermal remodeling due to prolonged muscle inactivity.
Revance Therapeutics (RVNC) reported a substantial revenue increase for Q2 2021, reaching $18.8 million, a surge from $0.3 million in Q2 2020. Total revenue for the first half of 2021 was $32.1 million compared to $0.4 million last year. The growth is attributed to the RHA® Collection of dermal fillers and fintech platform sales. However, net losses widened to $72.2 million for Q2 2021, up from $60.6 million in Q2 2020. The company anticipates FDA approval for DaxibotulinumtoxinA in 2021, which could significantly bolster its aesthetics franchise.
Revance Therapeutics (Nasdaq: RVNC) will announce its second quarter 2021 financial results on August 5, 2021, after market close. A conference call and live webcast will follow at 1:30 p.m. PT / 4:30 p.m. ET to discuss the outcomes and business updates. Individuals can access the call by dialing specified numbers or through the webcast on Revance's investor relations webpage. Revance focuses on innovative aesthetic and therapeutic solutions, including the DaxibotulinumtoxinA for Injection, which is nearing U.S. regulatory approval after a successful Phase 3 program.
Revance Therapeutics (Nasdaq: RVNC) announced that CEO Mark Foley will speak at two upcoming conferences. He will participate in the William Blair 41st Annual Growth Stock Conference on June 2, 2021, at 1:20 p.m. PT and the Goldman Sachs 42nd Annual Global Healthcare Conference on June 8, 2021, at 1:40 p.m. PT. Live audio webcasts will be accessible via the Investor Relations section of Revance's website, and a replay will be available for 30 days post-conference. Revance specializes in aesthetic and therapeutic offerings, including its innovative neuromodulator, DaxibotulinumtoxinA for Injection.
Revance Therapeutics, Inc. (Nasdaq: RVNC) announced that the FDA will initiate a pre-approval inspection of its manufacturing facility for DaxibotulinumtoxinA for Injection by the end of June 2021. This follows a deferral from the FDA in November 2020 due to COVID-19 travel restrictions affecting inspection completion. Revance's DaxibotulinumtoxinA is advanced for treating glabellar lines and is currently in a Phase 3 program. Revance is also developing a biosimilar to BOTOX® in partnership with Viatris.
FAQ
What is the current stock price of Revance Therapeutics (RVNC)?
What is the market cap of Revance Therapeutics (RVNC)?
What does Revance Therapeutics, Inc. specialize in?
What is the TransMTS® peptide delivery system?
What are the main products of Revance Therapeutics?
What is RT001?
What are the business segments of Revance Therapeutics?
How does Revance's TransMTS technology benefit its products?
What is the significance of DaxibotulinumtoxinA?
What is the RHA Collection?
What is the HintMD platform?
How does Revance's Product segment contribute to its revenue?
